In vitro immunoreactivity and in vivo neutralization of Trimeresurus gracilis venom with antivenoms targeting four pit viper species
Po-Chun Chuang,Jia-Wei Chen,Yuen-Ying Chan,Tsz-Chun Tse,Yu-Wei Chiang,Tein-Shun Tsai
DOI: https://doi.org/10.1371/journal.pntd.0012070
2024-03-27
PLoS Neglected Tropical Diseases
Abstract:Snakebite envenomation is a significant global health issue that requires specific antivenom treatments. In Taiwan, available antivenoms target a variety of snakes, but none specifically target Trimeresurus gracilis , an endemic and protected species found in the high mountain areas of Taiwan. This study evaluated the effectiveness of existing antivenoms against T . gracilis venom, focusing on a bivalent antivenom developed for Trimeresurus stejnegeri and Protobothrops mucrosquamatu s (TsPmAV), as well as monovalent antivenoms for Deinagkistrodon acutus (DaAV) and Gloydius brevicaudus (GbAV). Our research involved in vivo toxicity testing in mice and in vitro immunobinding experiments using (chaotropic) enzyme-linked immunosorbent assays, comparing venoms from four pit viper species ( T . gracilis , T . stejnegeri , P . mucrosquamatus , and D . acutus ) with three types of antivenoms. These findings indicate that TsPmAV partially neutralized T . gracilis venom, marginally surpassing the efficacy of DaAV. In vitro tests revealed that GbAV displayed higher binding capacities toward T . gracilis venom than TsPmAV or DaAV. Comparisons of electrophoretic profiles also reveal that T . gracilis venom has fewer snake venom C-type lectin like proteins than D . acutus , and has more P-I snake venom metalloproteases or fewer phospholipase A 2 than G . brevicaudus , T . stejnegeri , or P . mucrosquamatus . This study highlights the need for antivenoms that specifically target T . gracilis , as current treatments using TsPmAV show limited effectiveness in neutralizing local effects in patients. These findings provide crucial insights into clinical treatment protocols and contribute to the understanding of the evolutionary adaptation of snake venom, aiding in the development of more effective antivenoms for human health. Trimeresurus gracilis is a protected pit viper species endemic to the mid-to-high-altitude mountainous areas of Taiwan. Due to the lack of a serum specifically targeting T . gracilis envenomation, patients bitten by this species currently receive treatment by employing a bivalent antivenom developed against T . stejnegeri and P . mucrosquamatus , which is believed to potentially possess cross-neutralizing effects. However, the use of the bivalent antivenom has demonstrated limited effectiveness in neutralizing local effects in patients. In response, we conducted investigations into the in vitro immunological reactivity and in vivo neutralization of T . gracilis venom using antivenoms developed against four pit viper species. Our results indicate that the bivalent antivenom was not completely effective in neutralizing T . gracilis venom. Instead, the monovalent antivenom for Gloydius brevicaudus exhibited higher in vitro binding capacities toward T . gracilis venom compared with other antivenoms. These findings may be attributed to a closer phylogenetic relationship between T . gracilis and G . brevicaudus . Furthermore, these observations have the potential to contribute to the development of more effective antivenoms, offering valuable insights for the community focused on neglected tropical diseases.
tropical medicine,parasitology